iRegene Therapeutics Achieves Milestones in Neurodegenerative Disease Treatment iRegene Therapeutics has marked significant milestones in advancing cell therapies for Parkinson's and Multiple System Atrophy in the U.S. and China, showcasing their innovative strategies.

iRegene Therapeutics Achieves Milestones in Neurodegenerative Disease Treatment #China #Chengdu #Parkinson's #NouvNeu001 #iRegene

iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations iRegene Therapeutics has received dual FDA recognitions for NouvNeu001—highlighting its potential to transform Parkinson's treatment with innovative cell therapy.

iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations #NouvNeu001 #FDA_Designation #iRegene_Therapeutics

iRegene Therapeutics Unveils Promising Data from Phase I NouvNeu001 Trials Targeting Parkinson's Disease iRegene Therapeutics announces encouraging Phase I clinical data for NouvNeu001, a new therapy aiming to treat Parkinson's disease.

iRegene Therapeutics Unveils Promising Data from Phase I NouvNeu001 Trials Targeting Parkinson's Disease #China #Chengdu #Therapeutics #NouvNeu001 #iRegene